Grid Therapeutics is an emerging clinical stage biotechnology company located in Durham, North Carolina. They are committed to developing better and safer therapies for cancer. By harnessing the power of the human immune system, they are innovating cancer therapy.

Grid Therapeutics follows a unique strategy to rapidly and efficiently develop novel tumor-specific therapeutic antibodies for the treatment of multiple cancer types directly from single human B cells. They base their research and development on the fundamental principles of anti-tumor immunity. Their dedication to advancing cancer treatment is evident in their pursuit of groundbreaking therapies.

They have recently initiated a Phase 2 Investigator-Sponsored Trial of GT103 in Combination with Merck’s Pembrolizumab in Patients with Advanced NSCLC. Grid Therapeutics keeps patients and families informed about their progress through regular updates on cancer treatment and the search for a cure. They strive to make a significant impact in the fight against cancer and provide hope for a better future